These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17270028)

  • 1. Promoter methylation status of the Cyclin D2 gene is associated with poor prognosis in human epithelial ovarian cancer.
    Sakuma M; Akahira J; Ito K; Niikura H; Moriya T; Okamura K; Sasano H; Yaegashi N
    Cancer Sci; 2007 Mar; 98(3):380-6. PubMed ID: 17270028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter methylation of cyclin D2 gene in gastric carcinoma.
    Oshimo Y; Nakayama H; Ito R; Kitadai Y; Yoshida K; Chayama K; Yasui W
    Int J Oncol; 2003 Dec; 23(6):1663-70. PubMed ID: 14612939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.
    Henrique R; Costa VL; Cerveira N; Carvalho AL; Hoque MO; Ribeiro FR; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
    J Mol Med (Berl); 2006 Nov; 84(11):911-8. PubMed ID: 17016690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant methylation of the cyclin D2 promoter in primary small cell, nonsmall cell lung and breast cancers.
    Virmani A; Rathi A; Heda S; Sugio K; Lewis C; Tonk V; Takahashi T; Roth JA; Minna JD; Euhus DM; Gazdar AF
    Int J Cancer; 2003 Nov; 107(3):341-5. PubMed ID: 14506731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues.
    Matsubayashi H; Sato N; Fukushima N; Yeo CJ; Walter KM; Brune K; Sahin F; Hruban RH; Goggins M
    Clin Cancer Res; 2003 Apr; 9(4):1446-52. PubMed ID: 12684418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.
    Chou JL; Su HY; Chen LY; Liao YP; Hartman-Frey C; Lai YH; Yang HW; Deatherage DE; Kuo CT; Huang YW; Yan PS; Hsiao SH; Tai CK; Lin HJ; Davuluri RV; Chao TK; Nephew KP; Huang TH; Lai HC; Chan MW
    Lab Invest; 2010 Mar; 90(3):414-25. PubMed ID: 20065949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation.
    Evron E; Umbricht CB; Korz D; Raman V; Loeb DM; Niranjan B; Buluwela L; Weitzman SA; Marks J; Sukumar S
    Cancer Res; 2001 Mar; 61(6):2782-7. PubMed ID: 11289162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation.
    Akahira J; Sugihashi Y; Suzuki T; Ito K; Niikura H; Moriya T; Nitta M; Okamura H; Inoue S; Sasano H; Okamura K; Yaegashi N
    Clin Cancer Res; 2004 Apr; 10(8):2687-93. PubMed ID: 15102672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines.
    Kawamoto K; Hirata H; Kikuno N; Tanaka Y; Nakagawa M; Dahiya R
    Int J Cancer; 2008 Aug; 123(3):535-42. PubMed ID: 18404682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylation-associated silencing of the Wnt antagonist SFRP1 gene in human ovarian cancers.
    Takada T; Yagi Y; Maekita T; Imura M; Nakagawa S; Tsao SW; Miyamoto K; Yoshino O; Yasugi T; Taketani Y; Ushijima T
    Cancer Sci; 2004 Sep; 95(9):741-4. PubMed ID: 15471560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of 5-Aza-2'-deoxycytidine and trichostatin A on DNA methylation and expression of hMLH1 in ovarian cancer cell line COC1/DDP].
    Meng CF; Dai DQ; Guo KJ
    Ai Zheng; 2008 Dec; 27(12):1251-5. PubMed ID: 19079988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant promoter methylation of SPARC in ovarian cancer.
    Socha MJ; Said N; Dai Y; Kwong J; Ramalingam P; Trieu V; Desai N; Mok SC; Motamed K
    Neoplasia; 2009 Feb; 11(2):126-35. PubMed ID: 19177197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation.
    Padar A; Sathyanarayana UG; Suzuki M; Maruyama R; Hsieh JT; Frenkel EP; Minna JD; Gazdar AF
    Clin Cancer Res; 2003 Oct; 9(13):4730-4. PubMed ID: 14581343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promoter methylation status and expression of TMS1 gene in human epithelial ovarian cancer.
    Akahira J; Sugihashi Y; Ito K; Niikura H; Okamura K; Yaegashi N
    Cancer Sci; 2004 Jan; 95(1):40-3. PubMed ID: 14720325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin.
    Dhillon VS; Shahid M; Husain SA
    Mol Cancer; 2004 Dec; 3():33. PubMed ID: 15574200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin D2 expression in familial and sporadic breast cancer.
    Fischer H; Chen J; Skoog L; Lindblom A
    Oncol Rep; 2002; 9(6):1157-61. PubMed ID: 12375011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
    Shen DH; Chan KY; Khoo US; Ngan HY; Xue WC; Chiu PM; Ip P; Cheung AN
    Carcinogenesis; 2005 Apr; 26(4):855-63. PubMed ID: 15677627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway.
    Wang Z; Li M; Lu S; Zhang Y; Wang H
    Cancer Biol Ther; 2006 Mar; 5(3):256-60. PubMed ID: 16418574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylation of OPCML promoter in ovarian cancer tissues predicts poor patient survival.
    Zhou F; Tao G; Chen X; Xie W; Liu M; Cao X
    Clin Chem Lab Med; 2014 May; 52(5):735-42. PubMed ID: 24327526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
    Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
    Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.